Monoklonale Gammopathie unklarer Signifikanz und monoklonale B-Lymphozytose
作者： K. Hübel , M. Hallek
DOI: 10.1007/S00108-012-3215-2
关键词:
摘要: Die monoklonale Gammopathie unklarer Signifikanz (MGUS) und die B-Lymphozytose (MBL) sind asymptomatische Prakanzerosen, in eine therapiebedurftige, symptomatische Erkrankung ubergehen konnen. In der Regel wird Diagnose zufallig im Rahmen einer klinischen Routineuntersuchung gestellt. Da nur ein geringer Teil betroffenen Personen manifeste Krebserkrankung entwickelt, stellt sich Frage, inwieweit diese fruhzeitig identifizieren lassen. den vergangenen Jahren ermoglichte das zunehmende Verstandnis Pathogenese dieser Prakanzerosen auch Entwicklung von Risikomodellen, mithilfe derer individuelle Progressionsrisiko besser einschatzen lasst. Definition Hoch- Niedrigrisikopatienten optimiert damit klinische Management. vorliegende Arbeit fasst aktuellen Daten zur Biologie, Risikostratifikation, Verlaufsbeobachtung Patienten mit MGUS MBL zusammen.
springer.com
sci-hub.se 参考文章(20)
Nikhil C. Munshi, Kenneth C. Anderson, P. Leif Bergsagel, John Shaughnessy, Antonio Palumbo, Brian Durie, Rafael Fonseca, A. Keith Stewart, Jean-Luc Harousseau, Meletios Dimopoulos, Sundar Jagannath, Roman Hajek, Orhan Sezer, Robert Kyle, Pieter Sonneveld, Michele Cavo, S. Vincent Rajkumar, Jesus San Miguel, John Crowley, Hervé Avet-Loiseau, , Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2 Blood. ,vol. 117, pp. 4696- 4700 ,(2011) , 10.1182/BLOOD-2010-10-300970
T D Shanafelt, P Ghia, M C Lanasa, O Landgren, A C Rawstron, Monoclonal B-cell Lymphocytosis (MBL): Biology, Natural History, and Clinical Management Leukemia. ,vol. 24, pp. 512- 520 ,(2010) , 10.1038/LEU.2009.287
Celine M. Vachon, Robert A. Kyle, Terry M. Therneau, Barbara J. Foreman, Dirk R. Larson, Colin L. Colby, Tara K. Phelps, Angela Dispenzieri, Shaji K. Kumar, Jerry A. Katzmann, S. Vincent Rajkumar, Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance Blood. ,vol. 114, pp. 785- 790 ,(2008) , 10.1182/BLOOD-2008-12-192575
Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen S. Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley, Jerome B. Zeldis, Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Joshua Epstein, Shmuel Yaccoby, Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. ,vol. 112, pp. 3122- 3125 ,(2008) , 10.1182/BLOOD-2008-06-164228
Neha Korde, Sigurdur Y. Kristinsson, Ola Landgren, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies Blood. ,vol. 117, pp. 5573- 5581 ,(2011) , 10.1182/BLOOD-2011-01-270140
Andy C. Rawstron, Fiona L. Bennett, Sheila J.M. O'Connor, Marwan Kwok, James A.L. Fenton, Marieth Plummer, Ruth de Tute, Roger G. Owen, Stephen J. Richards, Andrew S. Jack, Peter Hillmen, Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia The New England Journal of Medicine. ,vol. 359, pp. 575- 583 ,(2008) , 10.1056/NEJMOA075290
Claudia Fazi, Lydia Scarfò, Lorenza Pecciarini, Francesca Cottini, Antonis Dagklis, Agnieszka Janus, Anna Talarico, Cristina Scielzo, Cinzia Sala, Daniela Toniolo, Federico Caligaris-Cappio, Paolo Ghia, General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. ,vol. 118, pp. 6618- 6625 ,(2011) , 10.1182/BLOOD-2011-05-357251
Giampaolo Merlini, Marvin J. Stone, Dangerous small B-cell clones Blood. ,vol. 108, pp. 2520- 2530 ,(2006) , 10.1182/BLOOD-2006-03-001164
Giada Bianchi, Robert A. Kyle, Colin L. Colby, Dirk R. Larson, Shaji Kumar, Jerry A. Katzmann, Angela Dispenzieri, Terry M. Therneau, James R. Cerhan, L. Joseph Melton, S. Vincent Rajkumar, Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications Blood. ,vol. 116, pp. 2019- 2025 ,(2010) , 10.1182/BLOOD-2010-04-277566
S. Vincent Rajkumar, Robert A. Kyle, Francis K. Buadi, Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence Mayo Clinic Proceedings. ,vol. 85, pp. 945- 948 ,(2010) , 10.4065/MCP.2010.0520